June 29, 2020
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating a new side effect risk of contrast encephalopathy for 10 imaging agents including Bayer Yakuhin’s Gastrografin (sodium amidotrizoate/amidotrizoate meglumine), a move likely to trigger label changes in the near future. The...read more